In a research initiative inspired by landmark dual immune checkpoint inhibitor (ICI) studies in human cancer, Vetigenics today announced dosing of the first patient in its CHECKMATE K9 pilot clinical study at the University of Wisconsin.
In a research initiative inspired by landmark dual immune checkpoint inhibitor (ICI) studies in human cancer, Vetigenics today announced dosing of the first patient in its CHECKMATE K9 pilot clinical study at the University of Wisconsin.